ライフサイエンスコーパス: grave

1 " manufacturing and the product end-of-life "grave").

2 before being deposited in a commingled mass grave.

3 se of flowers in the Shanidar IV Neanderthal grave.

4 found in a localized form, the prognosis is grave.

5 locally advanced and metastatic melanoma is grave.

6 and alkalinizing disturbances, many of them grave.

7 wo were between individuals buried in double graves.

8 known for such preparation and decoration of graves.

9 sets: 15 from the Late Bronze Age stone-cist graves (1200-400 BC) (EstBA) and 6 from the Pre-Roman Ir

10 used by antibiotic-resistant bacteria pose a grave and growing threat to public health.

11 nterpersonal Support Evaluation List-12, the Graven and Grant Social Network Survey, the Social Probl

12 ortem intervals (PMIs), locating clandestine graves, and obtaining soil and skin trace evidence.

13 d flower linings were found in four Natufian graves at the burial site of Raqefet Cave, Mt. Carmel, I

14 rparts ranging from 39 to 86% on a cradle-to-grave basis.

15 developed and incorporated into a cradle-to-grave boundary with a functional unit of 1 MJ of combust

16 ifestyle for several months and even in some grave cases lead to death.

17 Cognitive aspects of aging represent a grave challenge for our societal circumstances as member

18 ems, as carbapenem-resistant bacteria are of grave clinical concern and carbapenem-hydrolyzing enzyme

19 Central nervous system tumors carry grave clinical prognoses due to limited effectiveness of

20 eletal osteosarcoma (OS) has been considered grave compared with that for patients with relapse limit

21 proposed to play a role in liver fibrosis, a grave complication of biliary atresia (BA).

22 To reduce the probability of such a grave complication, preventive and precautionary measure

23 lining insect population sizes are provoking grave concern around the world as insects play essential

24 sulfate-reducing microorganisms (SRM) is of grave concern because of the associated health and facil

25 rds non-combatants on the battlefield are of grave concern in war.

26 n providing relief from this type of pain, a grave concern to the surgeons treating these soldiers.

27 ferences in innate drug resistance may be of grave consequences for disease management.

28 ramatic declines in insect abundance suggest grave consequences for global ecosystems and human socie

29 Hyperammonaemia in children can lead to grave consequences in the form of cerebral oedema, sever

30 rus (EBOV) disease epidemic demonstrated the grave consequences of filovirus epidemics in the absence

31 mall bowel, resulting, however, partially in grave consequences such as anemia.

32 se, either acute or chronic, has potentially grave consequences which include changes affecting the p

33 -long immunosuppression that can itself have grave consequences.

34 rough the cycle could result in defects with grave consequences.

35 mmon in critical illness and associated with grave consequences.

36 One grave difficulty is that even under well controlled cond

37 TSH receptor antibody-ELISA used to diagnose Graves disease ("third-generation assay") and also detec

38 oimmune thyroid diseases (AITDs), comprising Graves disease (GD) and Hashimoto thyroiditis (HT), deve

39 The major AITDs include Graves disease (GD) and Hashimoto's thyroiditis (HT); al

40 Graves disease (GD) is a common autoimmune thyroid disor

41 Graves disease (GD) is an autoimmune condition caused by

42 ence of hypoparathyroidism after surgery for Graves disease (GD) is lower after subtotal thyroidectom

43 s a common and debilitating manifestation of Graves disease (GD).

44 tibody generation in the autoimmune disorder Graves disease (GD).

45 cosis (OR = 0.76, p = 1.5 x 10(-3)), but not Graves disease (OR = 1.03, p = 0.82).

46 s associated with multiple factors including Graves disease [odds ratio (OR) = 2.06], lateral neck di

47 an increased risk of autoimmune thyroiditis, Graves disease and goitre to low selenium status.

48 tions causing endocrine dysfunctions such as Graves disease and hypo- and hyperthyroidism.

49 elopment of specific ligands useful to treat Graves disease and other dysfunctions of GPHRs.

50 ely 3% of women and 0.5% of men will develop Graves disease during their lifetime.

51 immune response to the TSHR, thereby causing Graves disease in genetically susceptible individuals.

52 Management of Graves disease includes treatment with antithyroid drugs

53 Graves disease is directly caused by thyroid-stimulating

54 The etiology of Graves disease is multifactorial, with nongenetic factor

55 Graves disease is the most common cause of persistent hy

56 Patients with Graves disease may be treated with antithyroid drugs, ra

57 are the primary therapy, but some women with Graves disease opt to receive definitive therapy with RA

58 imulating TSHR autoantibodies (TSHR-Ab's) in Graves disease patients may provide a functional explana

59 se a new adenovirus-mediated animal model of Graves disease to show that goiter and hyperthyroidism o

60 Treating Graves disease with RAI and surgery result in gland dest

61 unction (10 cases of hypothyroidism and 1 of Graves disease) developed in 11 of 19 (57.9%) of the DS

62 ne thyroid disease (Hashimoto thyroiditis or Graves disease), juvenile RA, inflammatory bowel disease

63 ue in both normal patients and patients with Graves disease), together with the humoral factors prese

64 Graves disease, a common organ-specific autoimmune disea

65 patients who have a history of treatment of Graves disease, a subgroup that is not a target of scree

66 ave relevance to the pathogenesis of orbital Graves disease, an inflammatory autoimmune condition tha

67 one was lost to follow-up, one developed of Graves disease, and one died of sepsis).

68 uding type 1 diabetes, rheumatoid arthritis, Graves disease, and systemic lupus erythematosus, are as

69 fibroblasts orchestrate tissue remodeling in Graves disease, at least in part, because they exhibit e

70 actors present in the serum of patients with Graves disease, forms the basis for the immunologic atta

71 erthyroidism are autoimmune hyperthyroidism (Graves disease, GD), toxic multinodular goiter (TMNG), a

72 s mellitus, psoriasis, rheumatoid arthritis, Graves disease, Hashimoto thyroiditis, Crohn disease, ul

73 ssues (thyroiditis, n = 3; psoriasis, n = 2; Graves disease, n 1; membranous glomerulonephritis, n =

74 In Graves disease, selenium supplementation might lead to f

75 rders involving a hyperactive thyroid gland (Graves disease, toxic multinodular goiter, toxic adenoma

76 to localized overproduction of hyaluronan in Graves disease.

77 an, hyaluronan, which accumulates in orbital Graves disease.

78 lating variety are the cause of hyperthyroid Graves disease.

79 and provide new insight into the etiology of Graves disease.

80 e receptor (TSHR), is the primary antigen of Graves disease.

81 halmopathy (TAO), an autoimmune component of Graves disease.

82 antibodies resembling those in patients with Graves disease.

83 ess is important in iodide deficiency and in Graves disease.

84 The most frequent cause is Graves' disease (autoimmune hyperthyroidism).

85 Autoimmune thyroid disease (AITD), including Graves' disease (GD) and Hashimoto's thyroiditis (HT), i

86 eported recently that IgG from patients with Graves' disease (GD) can induce the expression of the CD

87 II-encoded HLA-DRB1-DQA1-DQB1 haplotype with Graves' disease (GD) has been known for several years.

88 Graves' disease (GD) is a common autoimmune disease (AID

89 Graves' disease (GD) is a common thyroid disease, and Gr

90 Graves' disease (GD) is an autoimmune disease that prima

91 Graves' disease (GD) is an autoimmune process involving

92 Graves' disease (GD) is an autoimmune thyroid disease de

93 Graves' disease (GD) is associated with T cell infiltrat

94 Graves' disease (GD), an autoimmune process involving th

95 rbital fibroblasts (GOFB) from patients with Graves' disease (GD), as well as fibrocyte abundance, we

96 In autoimmune Graves' disease (GD), autoantibodies bind to the thyrotr

97 n's disease, and thyroid follicular cells in Graves' disease (GD).

98 athy are connective tissue manifestations of Graves' disease (GD).

99 most prevalent in hyperthyroid patients with Graves' disease (GD); however, severe cases of orbitopat

100 thyroid function and is targeted by IgGs in Graves' disease (GD-IgG).

101 t were analyzed in thyroid lobes affected by Graves' disease (n = 6), thyroid lobes with healthy tiss

102 disease (OR = 1.53; 95% CI, 1.12-2.10), and Graves' disease (OR = 1.33; 95% CI, 1.03-1.72) and negat

103 tis are more common than hyperthyroidism and Graves' disease (strong evidence).

104 This single autoantigenic target makes Graves' disease a prime candidate for Ag-specific immuno

105 In Graves' disease a specific combination of polymorphisms

106 [81.5%] females and 775 [18.5%] males) with Graves' disease and 16 756 controls (13 656 [81.5%] fema

107 les are more distal than those identified in Graves' disease and are in LD with Graves' disease prote

108 The autoimmune thyroid diseases (AITD), Graves' disease and chronic lymphocytic thyroiditis (CLT

109 m should be prioritised in the management of Graves' disease and early definitive treatment with radi

110 the common causes of thyrotoxicosis, such as Graves' disease and functioning nodular goiters, there a

111 ld of autoimmune thyroiditis (represented by Graves' disease and Hashimoto's thyroiditis) since Janua

112 ificant difference in the ADC values between Graves' disease and painless thyroiditis (P=0.001).

113 ighted MR imaging in differentiation between Graves' disease and painless thyroiditis.

114 hat manifest during the acute phase, such as Graves' disease and systemic lupus erythematosus, are di

115 Because of the low remission rate in Graves' disease and the inability to cure toxic nodular

116 for imaging of thyroid disorders, including Graves' disease and thyroid nodules.

117 thogenic TSHR Abs as detected using clinical Graves' disease assays.

118 (in total 42 agranulocytosis cases and 1,208 Graves' disease controls), using direct human leukocyte

119 e the preferred therapy for the treatment of Graves' disease during pregnancy.

120 e thyroid gland can be used to differentiate Graves' disease from painless thyroiditis in patients wi

121 sed as a threshold value for differentiating Graves' disease from painless thyroiditis, the best resu

122 Ag-specific immunotherapies aimed at curing Graves' disease in humans.

123 ance pathogenic Ab production and exacerbate Graves' disease in humans.

124 Treatment options for Graves' disease include antithyroid drugs, radioactive i

125 Graves' disease is an autoimmune disorder that causes hy

126 ntrol of hyperthyroidism among patients with Graves' disease is associated with improved survival com

127 Graves' disease is routinely treated with antithyroid dr

128 Graves' disease is the leading cause of hyperthyroidism

129 serve this association in the organ-specific Graves' disease or Addison's disease.

130 at least 1 member who had both SLE and AITD (Graves' disease or Hashimoto thyroiditis).

131 revious thyroid disease, particularly either Graves' disease or Hashimoto thyroiditis, suggesting the

132 umber in cohorts of patients with autoimmune Graves' disease or hepatitis B infection, whereas G138G

133 ulation iodine intake do not affect risk for Graves' disease or thyroid cancer, but correction of iod

134 tified in Graves' disease and are in LD with Graves' disease protective alleles identified in both of

135 Amiodarone-associated thyrotoxicosis and Graves' disease represented the main thyroid storm etiol

136 Graves' disease results from thyroid-stimulating Abs (TS

137 ither of the 2 SNPs recently associated with Graves' disease showed evidence for association in the u

138 The mean ADC value of the thyroid gland in Graves' disease was 2.03+/-0.28x10(-3) mm(2)/sec, and in

139 ween induced and spontaneous mouse models of Graves' disease with implications for potential immunoth

140 In 3 of the 14 regions, TCF7L2 (T2D), CTLA4 (Graves' disease) and CDKN2A-CDKN2B (T2D), much of the po

141 schizophrenia risk (rheumatoid arthritis and Graves' disease), and DICER1 is pivotal in miRNA process

142 thyroiditis) and autoimmune thyrotoxicosis (Graves' disease).

143 ion has been found in the thyroid condition, Graves' disease, as well as in mothers of homosexual men

144 s of risk of the common autoimmune disorders Graves' disease, autoimmune hypothyroidism and type 1 di

145 cells to human serum from two patients with Graves' disease, but not control sera, led to secretion

146 Patients with Graves' disease, defined by positive TRAb tests, were se

147 The most common cause of this syndrome is Graves' disease, followed by toxic multinodular goitre,

148 The most common cause of hyperthyroidism is Graves' disease, followed by toxic nodular goitre.

149 e 1 diabetes mellitus, rheumatoid arthritis, Graves' disease, Hashimoto thyroiditis, autoimmune thyro

150 ta, ankylosing spondylitis, dermatomyositis, Graves' disease, Hashimoto thyroiditis, insulin-dependen

151 f Trp(620) with another autoimmune disorder, Graves' disease, in 1,734 case and control subjects (P =

152 mulating autoantibodies (TSAb), the cause of Graves' disease, interact with this region of the TSHR i

153 halmopathy (TAO), an autoimmune component of Graves' disease, is associated with profound connective

154 in receptor (TSHR), the major autoantigen in Graves' disease, is posttranslationally modified by intr

155 rst identified as a potential autoantigen in Graves' disease, is similar to the tropomodulin (Tmod) f

156 ically to treat autoimmune diseases, such as Graves' disease, may also diminish pathological inflamma

157 t from PGP, predictions of Gilbert syndrome, Graves' disease, non-Hodgkin lymphoma, and various blood

158 opathy, a condition commonly associated with Graves' disease, remains inadequately treated.

159 his gene with type 1 diabetes mellitus (DM), Graves' disease, rheumatoid arthritis (RA), and multiple

160 Results: In Graves' disease, significantly higher deoxygenated hemog

161 In Graves' disease, the orbit of the eye can become severel

162 sues involved in Hashimoto's thyroiditis and Graves' disease, we performed ex vivo analysis of lympho

163 chanistic framework for molecular mimicry in Graves' disease, where early precursor B cells are expan

164 Graves' disease, which is autoimmune in nature, is the u

165 from a single experimental mouse undergoing Graves' disease, which shared the same H and L chain ger

166 tes (T2D), coronary artery disease (CAD) and Graves' disease.

167 manifestation most commonly associated with Graves' disease.

168 diseases, including rheumatoid arthritis and Graves' disease.

169 isease (TED) affects 25-50% of patients with Graves' Disease.

170 r immune responses localized to the orbit in Graves' disease.

171 iated with both type 1 diabetes mellitus and Graves' disease.

172 roduced from lymphocytes from a patient with Graves' disease.

173 tions for new studies on the pathogenesis of Graves' disease.

174 exon 33 SNP, giving an odds ratio of 6.1 for Graves' disease.

175 with HLA-DR3 in conferring susceptibility to Graves' disease.

176 loci for schizophrenia, type 1 diabetes, and Graves' disease.

177 of molecular mimicry in the pathogenesis of Graves' disease.

178 thod and effectiveness of primary therapy in Graves' disease.

179 contributing to the relative T3 toxicosis of Graves' disease.

180 des a single-atom modification that can have grave effects on the chemical and medicinal properties o

181 radiocarbon results suggest that megalithic graves emerged within a brief time interval of 200 y to

182 fe cycle assessment (LCA) measures cradle-to-grave environmental impacts of a product.

183 Adipocere samples obtained from grave exhumations were analysed using gas chromatography

184 lly available immunomodulatory therapies for Graves eye disease.

185 Grave faults in design and conduct of clinical trials ha

186 nt a detailed study of a Late Neolithic mass grave from southern Poland belonging to the Globular Amp

187 very common psychotic illnesses can carry a grave functional prognosis from the initial episode and

188 body orientation, treatment, and associated grave goods within a single feature and evidence for res

189 The human remains, grave goods, and associated fauna provide rare direct da

190 t feature with associated organic and lithic grave goods, including the earliest known North American

191 A prolonged course leads to remission of Graves' hyperthyroidism in about a third of cases.

192 Graves' hyperthyroidism is caused by autoantibodies to t

193 Because Graves' hyperthyroidism is preferentially induced in BAL

194 unoglobulin G purified from 38 patients with Graves' hyperthyroidism with AF (n=17) or sinus rhythm (

195 Graves' hyperthyroidism, a common autoimmune disease cau

196 When present in patients with Graves' hyperthyroidism, AAbeta1AR and AAM2R facilitate

197 he thyrotropin receptor (TSHR), the cause of Graves' hyperthyroidism, only develop in humans.

198 thy (GO) affects 50% to 60% of patients with Graves' hyperthyroidism, resulting in exophthalmos, peri

199 py, and is the preferred choice for relapsed Graves' hyperthyroidism.

200 copresence would facilitate AF in autoimmune Graves' hyperthyroidism.

201 n the genesis of atrial fibrillation (AF) in Graves' hyperthyroidism.

202 e of paediatric diarrhoea, with particularly grave impact on infants and immunocompromised individual

203 eart failure (HF) is a systemic illness with grave implications for bodily functions.

204 ease in Alzheimer disease (AD) worldwide has grave implications for individuals, family support syste

205 The results have grave implications for the vision research community who

206 Large identified plant impressions in the graves include stems of sage and other Lamiaceae (Labiat

207 e prognosis, and 17% were considered poor or grave, indicating that they were not expected to survive

208 syndrome-CoV 2 (SARS-CoV-2) pandemic, cause grave international public health concern.

209 Thrombosis and infections are two grave, interrelated problems associated with the use of

210 ce of CNT-FEDs, a screening-level, cradle-to-grave life cycle assessment (LCA) was conducted based on

211 Here a cradle-to-grave life cycle assessment from nanoparticle synthesis

212 cycle studies are used to inform a cradle-to-grave life cycle impact assessment.

213 light-duty vehicles should take a cradle-to-grave life cycle perspective and capture important regio

214 rt on uniquely preserved 13,700-11,700-y-old grave linings made of flowers, suggesting that such use

215 e floor chiseling to accommodate the desired grave location and depth is also evident at the site.

216 The cradle-to-grave model includes two sources of CO2: natural domes a

217 Despite the grave nature of these maladies, our understanding of the

218 There is a grave need for safer antiplatelet therapeutics to preven

219 rdiovascular abnormalities, often leading to grave neurological and behavioral consequences.

220 ication of hydrocephalus treatment, creating grave neurological consequences for patients, especially

221 Alternative etiologies of CN VI palsy with grave neurological implications often cannot be excluded

222 overed, paired and differentiated meteorites Graves Nunatak (GRA) 06128 and GRA 06129.

223 and the largest organic component of the CR2 Grave Nunataks (GRA) 95229 meteorite and found it to be

224 banon identified from the archaeology as the grave of Crusaders killed during a battle in the 13(th)

225 ssels that were found in Bronze and Iron Age graves of infants in Bavaria.

226 insurrection of 1916 and buried in a shallow grave on Cork prison's grounds.

227 Graves ophthalmopathy (GO) is an autoimmune disease that

228 The surgical management of Graves ophthalmopathy includes treatment of globe malpos

229 was a retrospective review of patients with Graves ophthalmopathy undergoing lower eyelid retraction

230 isease (GD) is a common thyroid disease, and Graves ophthalmopathy(GO) is the most common extra-thyro

231 ommendations only extending to patients with Graves ophthalmopathy, selenium supplementation is widel

232 ent of lower lid retraction in patients with Graves ophthalmopathy.

233 the basis for the immunologic attack seen in Graves ophthalmopathy.

234 Graves' ophthalmopathy (GO) affects 50% to 60% of patien

235 n 85 years, the efficacy of radiotherapy for Graves' ophthalmopathy (GO) has not been established con

236 Appearances of and increases in Graves' ophthalmopathy (GO) have been reported after tre

237 The patients had moderate, symptomatic Graves' ophthalmopathy (mean clinical activity score, 6.

238 The Graves' Ophthalmopathy Quality of Life (GO-QOL) scale wa

239 fic situations, for example, Duane syndrome, Graves' ophthalmopathy, may be particularly problematic.

240 lasts or fat accumulation, such as occurs in Graves' ophthalmopathy, tissue fibrosis, abnormal wound

241 and the mean change in overall score on the Graves' ophthalmopathy-specific quality-of-life (GO-QOL)

242 Clinical Activity Score, and results on the Graves' ophthalmopathy-specific quality-of-life question

243 the field, outline the optimal management of Graves orbitopathy and summarize the research developmen

244 The pathophysiology of Graves orbitopathy has also been revised with identifica

245 The presence of bifoveal fusion and/or Graves orbitopathy were risk factors for these adverse o

246 Graves orbitopathy, also known as thyroid eye disease or

247 TSHR autoantibodies also underlie Graves' orbitopathy (GO) and pretibial myxoedema.

248 Graves' orbitopathy (GO) is an autoimmune inflammatory d

249 ment of dysthyroid optic neuropathy (DON) in Graves' orbitopathy (GO).

250 ugs, of potential value for the treatment of Graves' orbitopathy.

251 and DWF were independent risk factors for a grave outcome.

252 nal failure in patients with HCV portended a grave outcome.

253 ivariable analyses were performed to predict grave outcomes (3-month modified Rankin Scale score of 5

254 at the maternal-fetal interface, often with grave outcomes to the developing fetus (i.e., Zika virus

255 The prevalence of grave outcomes was similarly high in the IWF (48.6%) and

256 nical thrombectomy, would be associated with grave outcomes.

257 A total of 32 Graves patients and 37 eyelids underwent lower eyelid re

258 d autoantigens after radio-iodine therapy in Graves patients.

259 pared between groups, the mean values of the Graves' patients differed from control at all angles (F

260 First, that activated T lymphocytes from Graves' patients drive the differentiation of PPAR-gamma

261 e TSHR on the functional response to TSAb in Graves' patients' sera.

262 Together, these findings give a cradle-to-grave picture of internal waves on a basin scale, which

263 Thus, grave preparation was a sophisticated planned process, e

264 Toxicity from radiation therapy is a grave problem for cancer patients.

265 GEP80 model identified 9% of patients with a grave prognosis among those with GEP70-defined low-risk

266 s a major health care problem because of its grave prognosis and the limited effectiveness of availab

267 HIV-associated TBM carries an especially grave prognosis and there are new data describing the op

268 of 74 intensive care unit patients who had a grave prognosis and were judged to be at high risk for d

269 Despite the strikingly grave prognosis for older patients with glioblastomas, s

270 specially of chromosome 13 (CA 13), confer a grave prognosis in multiple myeloma even with tandem aut

271 re common than primary CNS tumors and confer grave prognosis on patients, as existing treatments have

272 LR carries a grave prognosis, especially among the elderly and those

273 ell transplantation (alloSCT), and carries a grave prognosis.

274 ryptococcosis in patients with cirrhosis has grave prognosis.

275 types of lung cancers and is associated with grave prognosis.

276 s with aortic valve stenosis (AS) predicts a grave prognosis.

277 systemic AL amyloidosis is associated with a grave prognosis.

278 Chart documentation of "poor" or "grave" prognosis occurred "early": during induction, mai

279 esence of chromosome 13 deletion, which is a grave prognostic indicator in MM.

280 NPSLE patients, as determined by MRS, are a grave prognostic sign, indicating serious underlying his

281 ested repatriation under the Native American Graves Protection and Repatriation Act (NAGPRA).

282 avirus disease 2019 (COVID-19) pandemic is a grave public health crisis, causing massive disruption t

283 n the cardiovascular system, many times with grave results.

284 tric and systemic comorbidities; and carry a grave risk of mortality.

285 The COVID-19 pandemic is a particularly grave risk to the millions of Americans with opioid use

286 Due to the grave risks and complications of FT, it is important to

287 With the recently examined LBK mass grave site of Schoneck-Kilianstadten, Germany, we presen

288 Alzheimer's disease is a grave social problem in an aging population.

289 The analysis of grave soil samples with modern technology allows for the

290 Salmonella causes grave systemic infections in humans and other animals an

291 ommunity composition and structure, posing a grave threat to all amphibian populations.

292 iseases such as influenza continue to pose a grave threat to human health.

293 Antimicrobial resistance is a grave threat to human life.

294 ne fungus Sporisorium reilianum that poses a grave threat to maize production worldwide.

295 ry syndrome coronavirus 2 (SARS-CoV-2), is a grave threat to public health and the global economy.

296 ype 1 diabetes, rheumatoid arthritis, lupus, Graves thyroiditis, Addison disease and other autoimmune

297 ions, infectious diseases continue to take a grave toll on the population and economy of sub-Saharan

298 ons for disease pathogenesis: development of Graves TSHR Abs is limited by the availability of A-subu

299 In patients with Graves' upper eyelid retraction, the method demonstrated

300 physical monitoring of simulated clandestine graves using animal analogues.